We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
We are a team of access specialists with decades of experience working in the pharmaceutical, biotech and medical technology sectors, within industry, in consulting and in the policy arena.
Our aim is to provide you with the knowledge and understanding to help you address your access challenges, and to continue to keep up to date in this rapidly changing field.
Regular news articles and monthly newsletters keep you informed about important developments in access policy and practice worldwide.
We help access professionals understand the complex processes and policies they need to follow, ensuring that innovative treatments reach patients with minimal delay.
Our international calendar of events connects you directly to the latest thinking and developments in access and helps you to grow your professional network.
Ukraine has advanced a draft 2027 budget providing UAH21.7 billion for Affordable Medicines and UAH20.8 billion for centralised medicine and medical-device purchasing.
Italy proposes a three-year early-access programme for serious conditions without satisfactory treatment alternatives, funded from the existing Innovative Medicines Fund.
Italy’s draft 2027 Budget would raise the medicines direct-purchase spending ceiling from 2028 and reduce payback for manufacturers making additional domestic investments.
Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.
This two-day course explores the commercial contribution of pharmaceutical market access teams, including stakeholder prioritisation, understanding health systems, linking access activities to business strategy and cross-functional working.
A practical workshop applying AMCP real-world evidence standards to payer decision-making. Case-based exercises explore evidence credibility, study quality and how real-world findings can inform medicine coverage decisions.
How healthcare is financed, commissioned and delivered in England, Scotland, Wales and Northern Ireland, including provider organisation and patient charges.
How clinical and economic assessment shapes NHS medicines funding, including NICE appraisal, Scottish assessment and the arrangements in Wales and Northern Ireland.
The MHRA's procedures for authorising medicines in the UK, including national assessment, international recognition, conditional approval and coordination with NICE.